Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIDIL vs REMODULIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.
Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.
Heart failure: treatment to improve survival, prolong time to hospitalization, and improve quality of life in self-identified black patients with heart failure (NYHA class III-IV) receiving standard therapy (diuretics, ACE inhibitors/ARBs, beta-blockers). Off-label: none significant.
Pulmonary arterial hypertension (WHO Group I) to improve exercise capacity and reduce symptoms,Off-label: Severe Raynaud's phenomenon, digital ischemia, and salvage therapy for PAH in patients failing other prostacyclins
Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.
Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); isosorbide dinitrate: 1 hour (parent), 4-5 hours (isosorbide-5-mononitrate, active metabolite). Clinical context: Requires twice-daily dosing for sustained effect.
Terminal elimination half-life is approximately 4 hours (range 2-7 hours) following continuous subcutaneous infusion; clinical context: requires continuous infusion due to short half-life.
Isosorbide dinitrate: extensively metabolized by denitration and conjugation in the liver; hydralazine: primarily metabolized by N-acetylation (N-acetyltransferase 2, NAT2) and subsequent glucuronidation.
Hepatic metabolism via CYP2C8 and CYP2C9 (major), with minor contributions from CYP2C19 and CYP2D6; major metabolite is a glucuronide conjugate.
Hydralazine: 80% renal (as active drug and metabolites, predominantly N-acetylhydralazine and hydralazine pyruvic acid hydrazone); isosorbide dinitrate: renal (metabolites, primarily isosorbide mononitrates and isosorbide) and fecal (minor).
Renal: 20-30% as unchanged drug; fecal: 70-80% as metabolites (via biliary elimination).
Hydralazine: 87-90% (plasma proteins); isosorbide dinitrate: 30-40% (albumin).
Approximately 58% bound to human plasma proteins, primarily to albumin.
Hydralazine: 1.6 L/kg; isosorbide dinitrate: 2-4 L/kg. Clinical meaning: Extensive tissue distribution for both components.
Volume of distribution (Vd) is 1.3 L/kg (range 0.8-2.0 L/kg); clinical meaning: extensive distribution into tissues, exceeding total body water.
Hydralazine: 30-50% (oral, first-pass effect); isosorbide dinitrate: 20-30% (oral, extensive first-pass metabolism).
Subcutaneous: approximately 100% bioavailable compared to intravenous; oral: negligible (not administered orally).
No specific dose adjustment recommended; however, hydralazine is cleared renally and may accumulate in severe renal impairment (Cr Cl <30 m L/min); consider monitoring for adverse effects.
No dosage adjustment required for renal impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment but caution advised due to potential increased exposure.
Mild to moderate hepatic impairment (Child-Pugh class A or B): no adjustment. Severe hepatic impairment (Child-Pugh class C): contraindicated.
Safety and efficacy not established in pediatric patients; no standard dosing recommendations available.
Not established; safety and efficacy in pediatric patients have not been studied.
Initiate at lower end of dosing range; titrate slowly due to increased risk of hypotension and dizziness; monitor renal function as hydralazine clearance may decrease.
No specific dose adjustment recommended; use with caution due to age-related renal/hepatic decline.
None.
None. However, infusion site reactions (pain, erythema, induration) and risk of catheter-related bloodstream infections are significant concerns.
Hypotension (monitor blood pressure), agranulocytosis (rare; hydralazine may cause neutropenia; monitor CBC), drug-induced lupus-like syndrome (hydralazine; discontinue if symptoms develop), hepatotoxicity (hydralazine; monitor liver enzymes), risk of syncope when initiating or increasing dose, volume depletion (correct before use).
Sudden discontinuation may worsen PAH; taper if possible.,Infusion site reactions are common; avoid extravasation.,Risk of bleeding due to antiplatelet effects; use with caution in patients with peptic ulcer disease or on anticoagulants.,Hepatic impairment may increase exposure; dosage adjustment may be needed.,May cause systemic hypotension; monitor blood pressure.
Hypersensitivity to hydralazine or isosorbide dinitrate, severe hypotension (<100 mm Hg systolic), acute myocardial infarction (safety not established), cardiogenic shock, cardiomyopathy with restrictive/obstructive physiology, use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Known hypersensitivity to treprostinil or any excipient,Patients with severe hepatic impairment (Child-Pugh class C) due to lack of safety data
No specific food interactions. Avoid excessive alcohol intake as it may exacerbate hypotension.
There are no known food interactions with treprostinil. However, patients should maintain a balanced diet as part of overall PAH management. Grapefruit juice has not been reported to interact, but always consult with a healthcare provider.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hypotension, thrombocytopenia. Isosorbide dinitrate: Limited data; associated with methemoglobinemia in neonates. Use only if benefit outweighs risk.
Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate human data; however, based on animal findings, fetal risk cannot be excluded, particularly in the first trimester. In later trimesters, risks include potential fetal harm from maternal hypotension and hypoxia.
Hydralazine is excreted in breast milk (M/P ratio ~1.2); low levels unlikely to harm infant. Isosorbide dinitrate: No data on excretion. Monitor infant for hypotension. American Academy of Pediatrics considers hydralazine compatible with breastfeeding.
It is unknown if teriprostinil is excreted in human milk. M/P ratio not established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 48 hours after the last dose.
Pregnancy may increase volume of distribution and clearance of hydralazine; dose adjustments may be needed to maintain efficacy. Isosorbide dinitrate: no specific recommendations; start at lowest effective dose and titrate based on blood pressure response. Monitor for orthostatic hypotension.
Pregnancy is a contraindication; thus no dose adjustments are applicable. However, if used in exceptional circumstances, plasma volume expansion in pregnancy may alter drug distribution, but specific dose recommendations are lacking. Use is not recommended.
Bidil is a fixed-dose combination of isosorbide dinitrate (20 mg) and hydralazine (37.5 mg), indicated as an adjunct to standard therapy for heart failure in self-identified African American patients (NYHA class III-IV, left ventricular ejection fraction <45%). Dizziness and headache are common due to vasodilation; titrate slowly. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Monitor for fluid retention and worsening heart failure. Consider dose reduction in hepatic impairment.
REMODULIN (treprostinil) is a prostacyclin analog used for pulmonary arterial hypertension (PAH). Avoid abrupt discontinuation due to risk of rebound pulmonary hypertension. Monitor for infusion site reactions and bleeding risk due to antiplatelet effects. Dose titration should be guided by PAH symptoms and side effects. Use with caution in patients with hepatic impairment.
Take this medication exactly as prescribed, usually three times daily with or without food.,Do not take with erectile dysfunction drugs (e.g., Viagra, Cialis, Levitra) as this can cause a dangerous drop in blood pressure.,Common side effects include dizziness and headache, which may improve over time; report severe or persistent symptoms to your doctor.,Avoid sudden position changes to prevent falls.,Do not stop taking this medication abruptly without consulting your healthcare provider.,Inform all healthcare providers you are taking Bidil.,Store at room temperature, away from moisture and heat.
Do not stop taking this medication suddenly; sudden cessation may cause worsening of symptoms.,Report any signs of bleeding (e.g., easy bruising, nosebleeds, blood in urine or stool) to your healthcare provider.,If using subcutaneous infusion, rotate injection sites to prevent site reactions and infection.,Store medication as directed; do not freeze or expose to excessive heat.,Avoid activities that increase bleeding risk, such as contact sports, until you discuss with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIDIL vs REMODULIN, answered by our medical review team.
BIDIL is a Vasodilator Combination that works by Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.. REMODULIN is a Prostacyclin Vasodilator that works by Treprostinil is a synthetic prostacyclin analog that directly vasodilates pulmonary and systemic arterial beds, inhibits platelet aggregation, and suppresses smooth muscle proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIDIL and REMODULIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIDIL is: Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.. The standard adult dose of REMODULIN is: Continuous subcutaneous infusion: Initially 1.25 ng/kg/min; increase by 1.25 ng/kg/min every week for first 4 weeks, then by 2.5 ng/kg/min every week as tolerated. Intravenous infusion: same dosing.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIDIL and REMODULIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIDIL is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hyp. REMODULIN is classified as Category C. Teriprostinil (REMODULIN) is contraindicated in pregnancy due to teratogenic effects in animal studies (increased cardiovascular and skeletal malformations). There are no adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.